PNS Notification from Sedgwick | |
Initiated by : Grifols Therapeutics LLC Event Id : 222 Event Date : 03-04-2025 |
![]() |
Therapy |
|
|||||||||||||||
Reason | This is to inform you that Grifols Therapeutics is initiating a voluntary withdrawal of one lot of Gamunex-C 10%, 40G Vial, as detailed below. Grifols is committed to providing the highest quality medicines in the market. This voluntary withdrawal is being conducted as a precautionary measure due to an increased rate of allergic/hypersensitivity type reactions associated with this specific lot. A small number of the reactions were considered medically significant. Hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with immune globulin products. This withdrawal is being conducted with the knowledge of the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. |
|||||||||||||||
Action | Please examine your stock immediately to determine if you have any of the above-mentioned lots on hand. If you have product from this lot, cease use of the product immediately. Return the affected product to the point of purchase to receive replacement product. |
|||||||||||||||
Other Information | If you have technical or clinical questions, please contact US Clinical Communications at (800) 520-2807 |